LABU240816C104000
- 24.46
- +3.96+19.32%
Direxion Daily S&P Biotech Bull 3x Shares ETF Newsroom
TD Cowen Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,230
TD Cowen Maintains United Therapeutics(UTHR.US) With Buy Rating, Maintains Target Price $350
Alnylam Pharmaceuticals Analyst Ratings
Jefferies Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $380
A Quick Look at Today's Ratings for Gilead Sciences(GILD.US), With a Forecast Between $76 to $85
Jefferies Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $380
Goldman Sachs Upgrades Alnylam Pharmaceuticals(ALNY.US) to Buy Rating, Raises Target Price to $370
Buy Rating Affirmed for Alnylam Pharmaceuticals on Strong Amvuttra Trial Results and Robust Market Potential
A Quick Look at Today's Ratings for Gilead Sciences(GILD.US), With a Forecast Between $76 to $85
TD Cowen Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $381
Gilead Sciences Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Korro Bio (KRRO) and Gilead Sciences (GILD)
Hold Rating on Gilead Sciences Amid Modest PBC Market Impact
Analysts Conflicted on These Healthcare Names: Arcutis Biotherapeutics (ARQT), Gilead Sciences (GILD) and Cardinal Health (CAH)
Barclays Sticks to Their Hold Rating for Gilead Sciences (GILD)
Analysts Offer Insights on Healthcare Companies: Immunocore Holdings (IMCR), Natera (NTRA) and Disc Medicine (IRON)
Morgan Stanley Maintains Natera(NTRA.US) With Buy Rating, Raises Target Price to $132
J.P. Morgan Sticks to Their Buy Rating for Natera (NTRA)
BMO Capital Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Raises Target Price to $300
Piper Sandler Maintains Natera(NTRA.US) With Buy Rating, Raises Target Price to $150